Intravas

Enoxaparin Na

DVT w/ or w/o pulmonary embolism; unstable angina & non-Q-wave MI, administered concurrently w/ aspirin. Prevention of thrombus formation in the extra-corporal circulation during hemodialysis. Prophylaxis of venous thromboembolic disease, particularly those which may be associated w/ orthopedic or general, major colorectal or cancer surgery; venous thromboembolic disease in medical patients bedridden due to acute illness including acute heart failure, resp failure, severe infections & rheumatic diseases.

Adult <75 yr DVT or pulmonary embolism 1.5 mg/kg (150 U/kg) 24 hrly, usually for at least 5 days, & until adequate oral anticoagulation is established. Acute ST-segment elevation MI 30 mg (3,000 U) IV 1 mg/kg (100 U/kg), 1 mg/kg SC 12 hrly for up to 8 days. Max: 100 mg (10,000 U) for 1st 2 SC doses only. Patients undergoing percutaneous coronary intervention: Additional dose, 300 mcg/kg (30 U/kg) IV at time of procedure, if last SC dose given >8 hr previously. Note: When administered in conjunction w/ a thrombolytic, give between 15 min before & 30 min after the start of thrombolytic therapy. Unstable angina & non-ST-segment elevation MI 1 mg/kg (100 U/kg) SC 12 hrly usually for 2-8 days. Min: 2 days. Venous thromboembolism in pregnancy Early pregnancy <50 kg: 40 mg (4,000 U) SC bd. 50-70 kg: 60 mg (6,000 U) bd. 70-90 kg: 80 mg (8,000 U) SC bd. >90 kg: 100 mg (10,000 U) SC bd. Prevention of clotting in extracorporeal circuits Recommended dose: 1 mg/kg. Patients w/ high risk of hemorrhage: Reduce to 0.5 mg/kg for double vascular access or 0.75 mg/kg for singular vascular access. May give further dose 0.5-1 mg/kg, if fibrin rings are found eg, after prolonged session. DVT prophylaxis especially in surgical patients Moderate risk: 20 mg (2,000 U) SC approx 2 hr before surgery, then 20 mg (2,000 U) 24 hrly for 7-10 days. High risk (eg, orthopedic surgery): 40 mg (4,000 U) SC 12 hr before surgery, then 40 mg (4,000 U) 24 hrly for 7-10 days. DVT prophylaxis in medical patients 40 mg (4,000 U) SC 24 hrly for at least 6 days, continued until patient ambulant. Max: 14 days. Elderly >75 yr Acute ST-segment elevation MI 750 mcg/kg (75 U/kg) SC only 12 hrly. Max: 75 mg (7,500 U) for 1st 2 doses only.

Hypersensitivity to either enoxaparin, heparin or other LMWH. Major clotting disorders eg, history of thrombocytopenia, active GI ulcer or organic lesion likely to bleed, recent hemorrhagic vascular cerebral stroke.

Not for IM administration. Conditions w/ increased potential for bleeding, (eg, impaired hemostasis, history of peptic ulcer, recent ischemic stroke, uncontrolled severe arterial HTN, diabetic retinopathy, recent neuro or ophth surgery & low wt patients). Measure platelet count prior to initiation & regularly thereafter during treatment. Pregnancy & lactation.

Hemorrhage, thrombocytopenia, local reactions (pain, hematoma & mild local irritation). Neuraxial haematomas.

Concurrent use w/ spiral or epidural anesth or spiral puncture may result to varying degrees of neurological injuries.

Anticoagulants, Antiplatelets & Fibrinolytics (Thrombolytics)

B01AB05 - enoxaparin ; Belongs to the class of heparin group. Used in the treatment of thrombosis.

POM